Table 3. Characteristics of patients with intermediate-cytogenetic risk according to the type of anthracycline used at induction treatment.
| No DNMT3A exon 23 mutation | DNMT3A exon 23 mutation | p | |||
|---|---|---|---|---|---|
| DNR | IDA | DNR | IDA | ||
| Sex - no. | |||||
| Male | 39 | 20 | 8 | 6 | 0.16 |
| Female | 48 | 13 | 17 | 5 | |
| Age - y | |||||
| Median | 49 | 50 | 47 | 46 | 0.81 |
| Range | 21-60 | 18-60 | 20-60 | 35-60 | |
| WBC - G/L | |||||
| Median | 14.5 | 17.9 | 52 | 41.3 | 0.0037 |
| Range | 0.8-356 | 1.8-220 | 1.7-249 | 1.0-250 | |
| Mutations - no. /total no. (%) | |||||
| FLT3-ITD | 20/87 (23) | 11/33 (33) | 11/25 (44) | 4/11 (36) | 0.19 |
| NPM1 | 30/87 (34) | 5/33 (15) | 19/25 (76) | 8/11 (73) | <0.0001 |
| CEBPA | 12/87 (13) | 6/33 (18) | 2/25 (8) | 0/11 (0) | 0.38 |
| IDH1 | 11/87 (13) | 2/33 (6) | 6/25 (24) | 2/11 (18) | 0.24 |
| IDH2 | 10/87 (11) | 2/33 (6) | 3/25 (12) | 1/11 (9) | 0.83 |
| Complete response - no. (%) | 73/87 (84) | 25/33 (76) | 22/25 (88) | 10/11 (91) | 0.53 |
| Allogeneic SCT - no./total no. (%) | 27/73 (36) | 11/25 (44) | 10/22 (45) | 5/10 (50) | 0.71 |
| Relapse - no./total no. (%) | 32/73 (44) | 17/25 (68) | 12/22 (55) | 1/10 (10) | 0.014 |
| 5-year survival (%) | 40.1 | 26.9 | 41.4 | 72.7 | - |
DNR, daunorubicin; IDA, idarubicin; WBC, white blood cell count; SCT, stem cell transplantation.